Abstract
Objectives: Psoriasis is a common chronic recurrent dermatitis. Accumulating observations show gut microbiota dysbiosis in psoriasis. We intend to further investigate the relationship between intestinal microbiota and psoriasis development.Design: We first performed an epidemiological investigation on differences of gastrointestinal discomfort symptoms between patients with psoriasis and general population. Then variation of gut microbiota in patients with psoriasis (un)treated with acitretin plus narrow-band ultraviolet B (NB-UVB) was analyzed by 16S rRNA sequencing. We last compared recovery status and vital cytokines (lesion and intestine) of mouse psoriasiform models, which were transplanted with fecal microbiota from patients with psoriasis or healthy controls.Results: (1) About 85.5% of patients with psoriasis vs. 58.1% of healthy controls presented with at least one gastrointestinal symptom. The prevalence of investigated symptoms (e.g., abdominal distension and constipation) were significantly higher in patients, compared with controls (p < 0.05). Passing flatus and constipation were significantly correlated with psoriasis (p < 0.05 in both cases). (2) The abundance of Ruminococcaceae family, Coprococcus_1 genus, and Blautia genus were decreased with psoriasis improvement (p < 0.05, respectively), which had been demonstrated significantly increased in psoriasis. (3) Mice receiving psoriatic microbes transplantation showed delayed recovery of psoriasiform dermatitis and less reduction of interleukin (IL)-17A than those receiving healthy microbiota or blank control (p < 0.05 and p < 0.01, respectively).Conclusion: Multiple evidence we provided here preliminarily demonstrates the involvement of gut microbiota in the different degree of psoriasis activity. The strategy based on overall microbial communities is expected to be a promising supplementary for long-term management of psoriasis.
Highlights
Psoriasis is a common chronic skin inflammation, and it can even cause systemic involvement for those with early-onset and severe conditions [1]
Multiple evidence we provided here preliminarily demonstrated the involvement of gut microbiota in psoriasis development
To further understand the relationship between gut microbiota and the degree of psoriasis activity, we investigated the variation in bacteria community of patients with psoriasis who were effectively treated by acitretin plus narrow-band ultraviolet B (NB-UVB)
Summary
Psoriasis is a common chronic skin inflammation, and it can even cause systemic involvement for those with early-onset and severe conditions [1]. The exact pathogenesis is not completely known, psoriasis has been considered a relapsing-remitting disease triggered by environment–immunity interaction in genetically susceptible individuals. The concept of gut–skin axis has linked the disordered gut microbiome and skin diseases through a network of inflammatory mediators [4, 5]. Evidence suggests that lower gut microbiome diversity is associated with higher levels of fat and low-grade chronic inflammatory process [6]. Dysbiosis in microbial communities has been implicated in continuous immunological stimulation, as a trigger for local and (or) systemic immune responses, including inflammatory bowel disease (IBD) and allergy [7, 8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
